|
1
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katoh H, Yamashita K, Wang G, Sato T,
Nakamura T and Watanabe M: Anastomotic leakage contributes to the
risk for systemic recurrence in stage II colorectal cancer. J
Gastrointest Surg. 15:120–129. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Katoh H, Yamashita K, Wang G, Sato T,
Nakamura T and Watanabe M: Prognostic significance of preoperative
bowel obstruction in stage III colorectal cancer. Ann Surg Oncol.
18:2432–2441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamashita K and Watanabe M: Clinical
significance of tumor markers and an emerging perspective on
colorectal cancer. Cancer Sci. 100:195–199. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katoh H, Yamashita K, Sato T, Ozawa H,
Nakamura T and Watanabe M: Prognostic significance of peritoneal
tumour cells identified at surgery for colorectal cancer. Br J
Surg. 96:769–777. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato T, Yasui K, Hirai T, Kanemitsu Y,
Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results
for hepatic metastasis of colorectal cancer with special reference
to effectiveness of hepatectomy: Analysis of prognostic factors for
763 cases recorded at 18 institutions. Dis Colon Rectum. 46 10
Suppl:S22–S31. 2003.PubMed/NCBI
|
|
7
|
Nakamura T, Yamashita K, Sato T, Ema A,
Naito M and Watanabe M: Neoadjuvant chemoradiation therapy using
concurrent S-1 and irinotecan in rectal cancer: Impact on long-term
clinical outcomes and prognostic factors. Int J Radiat Oncol Biol
Phys. 89:547–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wong SL, Mangu PB, Choti MA, Crocenzi TS,
Dodd GD III, Dorfman GS, Eng C, Fong Y, Giusti AF, Lu D, et al:
American Society of Clinical Oncology 2009 clinical evidence review
on radiofrequency ablation of hepatic metastases from colorectal
cancer. J Clin Oncol. 28:493–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Final results from PRIME: Randomized phase III
study of panitumumab with FOLFOX4 for first-line treatment of
metastatic colorectal cancer. Ann Oncol. 25:1346–1355. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmuller
C, Kahl C, et al: FOLFIRI plus cetuximab versus FOLFIRI plus
bevacizumab as first-line treatment for patients with metastatic
colorectal cancer (FIRE-3): A randomised, open-label, phase 3
trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diaz LA Jr, Williams RT, Wu J, Kinde I,
Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al:
The molecular evolution of acquired resistance to targeted EGFR
blockade in colorectal cancers. Nature. 486:537–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moroni M, Veronese S, Benvenuti S,
Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M,
Siena S and Bardelli A: Gene copy number for epidermal growth
factor receptor (EGFR) and clinical response to antiEGFR treatment
in colorectal cancer: A cohort study. Lancet Oncol. 6:279–286.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD,
Chung TH, Chng WJ and Zeng Q: Metastasis-associated PRL-3 induces
EGFR activation and addiction in cancer cells. J Clin Invest.
123:3459–3471. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vogelstein B and Kinzler KW: The path to
cancer-three strikes and you're out. N Engl J Med. 373:1895–1898.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashton-Rickardt PG, Dunlop MG, Nakamura Y,
Morris RG, Purdie CA, Steel CM, Evans HJ, Bird CC and Wyllie AH:
High frequency of APC loss in sporadic colorectal carcinoma due to
breaks clustered in 5q21-22. Oncogene. 4:1169–1174. 1989.PubMed/NCBI
|
|
19
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Linsalata M, Notarnicola M, Caruso MG, Di
Leo A, Guerra V and Russo F: Polyamine biosynthesis in relation to
K-ras and P-53 mutations in colorectal carcinoma. Scand J
Gastroenterol. 39:470–477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buffart TE, Coffa J, Hermsen MA, Carvalho
B, van der Sijp JR, Ylstra B, Pals G, Schouten JP and Meijer GA:
DNA copy number changes at 8q11-24 in metastasized colorectal
cancer. Cell Oncol. 27:57–65. 2005.PubMed/NCBI
|
|
22
|
Sugimachi K, Niida A, Yamamoto K,
Shimamura T, Imoto S, Iinuma H, Shinden Y, Eguchi H, Sudo T,
Watanabe M, et al: Allelic imbalance at an 8q24 oncogenic SNP is
involved in activating MYC in human colorectal cancer. Ann Surg
Oncol. 21 Suppl 4:S515–S521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ooki A, Yamashita K, Kikuchi S, Sakuramoto
S, Katada N and Watanabe M: Phosphatase of regenerating liver-3 as
a convergent therapeutic target for lymph node metastasis in
esophageal squamous cell carcinoma. Int J Cancer. 127:543–554.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ooki A, Yamashita K, Kikuchi S, Sakuramoto
S, Katada N, Waraya M, Kawamata H, Nishimiya H, Nakamura K and
Watanabe M: Therapeutic potential of PRL-3 targeting and clinical
significance of PRL-3 genomic amplification in gastric cancer. BMC
Cancer. 11:1222011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hatate K, Yamashita K, Hirai K, Kumamoto
H, Sato T, Ozawa H, Nakamura T, Onozato W, Kokuba Y, Ihara A and
Watanabe M: Liver metastasis of colorectal cancer by
protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through
lymph node metastasis and elevated serum tumor markers such as CEA
and CA19-9. Oncol Rep. 20:737–743. 2008.PubMed/NCBI
|
|
26
|
Nakayama N, Yamashita K, Tanaka T,
Kawamata H, Ooki A, Sato T, Nakamura T and Watanabe M: Genomic gain
of the PRL-3 gene may represent poor prognosis of primary
colorectal cancer, and associate with liver metastasis. Clin Exp
Metastasis. 33:3–13. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saha S, Bardelli A, Buckhaults P,
Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C,
Kinzler KW and Vogelstein B: A phosphatase associated with
metastasis of colorectal cancer. Science. 294:1343–1346. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zimmerman MW, Homanics GE and Lazo JS:
Targeted deletion of the metastasis-associated phosphatase Ptp4a3
(PRL-3) suppresses murine colon cancer. PLoS One. 8:e583002013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee JC, Wang ST, Chow NH and Yang HB:
Investigation of the prognostic value of coexpressed erbB family
members for the survival of colorectal cancer patients after
curative surgery. Eur J Cancer. 38:1065–1071. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Porebska I, Harlozińska A and Bojarowski
T: Expression of the tyrosine kinase activity growth factor
receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and
adenomas. Tumour Biol. 21:105–115. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Allegra CJ, Jessup JM, Somerfield MR,
Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and
Schilsky RL: American Society of Clinical Oncology provisional
clinical opinion: Testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Saltz LB, Meropol NJ, Loehrer PJ Sr,
Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in
patients with refractory colorectal cancer that expresses the
epidermal growth factor receptor. J Clin Oncol. 22:1201–1208. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balin-Gauthier D, Delord JP, Rochaix P,
Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P and Allal C: In
vivo and in vitro antitumor activity of oxaliplatin in combination
with cetuximab in human colorectal tumor cell lines expressing
different level of EGFR. Cancer Chemother Pharmacol. 57:709–718.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fiordalisi JJ, Dewar BJ, Graves LM,
Madigan JP and Cox AD: Src-mediated phosphorylation of the tyrosine
phosphatase PRL-3 is required for PRL-3 promotion of Rho
activation, motility and invasion. PLoS One. 8:e643092013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liang F, Liang J, Wang WQ, Sun JP, Udho E
and Zhang ZY: PRL3 promotes cell invasion and proliferation by
down-regulation of Csk leading to Src activation. J Biol Chem.
282:5413–5419. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang H, Quah SY, Dong JM, Manser E, Tang
JP and Zeng Q: PRL-3 down-regulates PTEN expression and signals
through PI3K to promote epithelial-mesenchymal transition. Cancer
Res. 67:2922–2926. 2007. View Article : Google Scholar : PubMed/NCBI
|
